Drug Type Biosimilar, Monoclonal antibody |
Synonyms Dupilumab Biosimilar (Chime Biologics Ltd./Daewoong Pharmaceutical Co., Ltd.), 度普利尤单抗生物类似药(鼎康(武汉)生物医药有限公司/Daewoong Pharmaceutical Co., Ltd.) |
Target |
Action inhibitors |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors), IL-4 inhibitors(Interleukin-4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |


| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Immune System Diseases | Preclinical | China | 02 Jun 2026 | |
| Immune System Diseases | Preclinical | South Korea | 02 Jun 2026 |






